BDi Biotechnology Group

What BDi Biotechnology Group does

BDi Biotechnology Group (legal entity BIOTECHNOLOGY DEVELOPMENT FOR INDUSTRY IN PHARMACEUTICALS, S.L.U.) is a Spanish Contract Development and Manufacturing Organization (CDMO) founded in 2016 and headquartered at Boecillo Technological Park in Valladolid, Spain. The company operates as an external R&D and manufacturing department for clients developing biotechnological products, providing services spanning microbial strain development, bioprocess design and scale-up, and contract manufacturing under ISO 9001, ISO 13485, and cGMP standards across bioreactor scales from 1L to 2000L.

The company's core technology rests on multiple microbial expression platforms — bacteria (E. coli, Bacillus), yeast (Saccharomyces, Pichia), and fungi (Trichoderma, Aspergillus) — supported by a proprietary, IP-free molecular toolkit of base strains, plasmids, promoters, and signal sequences. Infrastructure includes more than 4,550 m² of purpose-built facilities with bioreactors, downstream processing (centrifugation, multiple filtration modes, high-pressure homogenization, liquid chromatography), and full analytical laboratories (HPLC, UPLC-MS, PCR/qPCR, electrophoresis). A multidisciplinary team of more than 60 scientists has delivered more than 200 projects and managed more than €500M in R&D project value.

BDI biotech generates revenue through fee-for-service, project-based contracts with no proprietary product catalog. The company serves four primary verticals: nutraceuticals (primary segment, including dietary enzymes, pre/probiotics, and dairy proteins), cosmetics (enzymes, natural pigments, skin probiotics), Live Biotherapeutic Products (cell banking, process development, cGMP manufacturing), and food/agroindustrial applications (cultured meat, single-cell proteins, by-product valorization). Clients range from startups to multinationals and are engaged through direct B2B outreach, with project scoping and pricing conducted on a custom quote basis. Distribution is direct-to-client with no third-party channels, and operating geographies are claimed as both Europe and global from the single Spanish facility.

Name

BDi Biotechnology Group

Legal name

BIOTECHNOLOGY DEVELOPMENT FOR INDUSTRY IN PHARMACEUTICALS, S.L.U.

Website

https://bdibiotech.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

BDi Biotechnology Group is a Spanish CDMO providing microbial strain development, bioprocess scale-up, and cGMP contract manufacturing services to nutraceutical, cosmetic, live biotherapeutic, and food industry clients from its Boecillo, Valladolid facility.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Contract Development and Manufacturing (CDMO)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Enzymes & Industrial Biotechnology Inputs (Enzymes, Microbial Strains, Fermentation Aids) (EUAAAIAL)

akta.pro secondary industries

Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts) (CRADAOAI), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

Keywords

• Microbial contract manufacturing
• Biopharmaceutical CDMO services
• Live biotherapeutic products
• Precision fermentation solutions
• Strain and bioprocess development

Headquarters

HQ city

Boecillo

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain

Revenue model

1. Contract Development and Manufacturing Services (CDMO): The company provides fee-for-service biotech R&D and manufacturing services to third-party clients. Services include strain development, bioprocess development, scale-up, and contract production across nutraceuticals, cosmetics, and live biotherapeutic products. Revenue is generated on a project-by-project basis, with no proprietary product catalog.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

BDi Biotechnology Group provides contract development and manufacturing services built on proprietary microbial biotechnology platforms. It offers strain and cell banking development, bioprocess design and scale-up, and GMP-capable production of recombinant proteins, enzymes, probiotics, dairy proteins, and live biotherapeutic products for nutraceutical, cosmetic, food, and pharmaceutical clients.

Product overview

BDI biotech operates as a Contract Development and Manufacturing Organization (CDMO) providing a comprehensive suite of biotech services without maintaining its own product catalog. The company functions as an external R&D department specialized in strain and bioprocess development, scale-up, and batch production. Services include Strain Development and Cell Banking (bacteria, yeast, fungi platforms), Bioprocess Development and Scale-Up, Contract Manufacturing (ISO9001, ISO13485, cGMP), Analytical Methods Development, and Project Evaluations. The company serves three primary sectors: Live Biotherapeutic Products (LBPs) with manufacturing up to 2000L, Cosmetics with enzyme and probiotic services, and Nutraceuticals with dietary enzymes, pre/probiotics, and dairy proteins. The company has completed over 200 projects and manages over 500M euros in successful R&D projects.

Differentiator

Problem solved

Functional benefit

Products and services

• Strain Development and Cell Banking Custom microbial strain engineering, host selection, and master/working cell bank preparation for recombinant protein and live biotherapeutic production, delivered to nutraceutical, cosmetic, food, and pharmaceutical clients.
• Bioprocess Development and Scale-Up
• Contract Manufacturing (Microbial CDMO Production)
• Live Biotherapeutic Products (LBP) Development and Manufacturing
• Specialty Enzyme Production
• Precision-Fermented Dairy Proteins
• Probiotics Production
• Nutraceutical Bio-Ingredient Services
• Cosmetic Bio-Active Ingredient Services
• Cultured Meat and Alternative Protein Bioprocess Services
• Flavorings and High-Value Bioproduct Services
• Biotransformation Services
• Project Evaluation and Feasibility Services

Quantifiable outcome

• More than 200 projects successfully completed since 2016
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core.

• ArgalcoreStrategic or Co-development PartnerArgal serves as the project leader for the CULTUREDMEAT consortium, an R&D initiative investigating cultivated meat for the prevention of colon cancer and dyslipemias. The project was submitted to the CDTI MISSIONS call and is the most highly evaluated proposal in Spain (2020), involving 8 partner companies and 10 research organizations.
• Biotech FoodscoreStrategic or Co-development PartnerBiotech Foods is one of 8 partner entities in the CULTUREDMEAT consortium working on cellular agriculture research for cultivated meat destined for the prevention of colon cancer and dyslipemias.
• Martínez SomalocoreStrategic or Co-development PartnerMartínez Somalo is one of 8 partner entities in the CULTUREDMEAT consortium, contributing to the development of meat products from cellular agriculture alongside 10 research organizations.
• DMC ResearchcoreStrategic or Co-development PartnerDMC Research participates as one of 8 partner entities in the CULTUREDMEAT consortium, a CDTI-funded R&D project on cultivated meat for health applications.
• NeoalgaecoreStrategic or Co-development PartnerNeoalgae is one of 8 partner entities in the CULTUREDMEAT consortium, contributing biotechnology expertise to the development of functional meat products.
• BTSAcoreStrategic or Co-development PartnerBTSA is one of 8 partner entities in the CULTUREDMEAT consortium, collaborating on research into meat produced from cellular agriculture.
• AgrowingdatacoreStrategic or Co-development PartnerAgrowingdata participates in the CULTUREDMEAT consortium as one of 8 partner companies, contributing to the CDTI MISSIONS R&D project on cultivated meat.
• ZABALA InnovationcoreStrategic or Co-development PartnerZABALA Innovation leads the management of the CULTUREDMEAT project, leveraging its extensive experience in R&D grant applications and project administration to support the consortium's objectives in cultivated meat research.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• 53Biologics: Microbial CDMO located at the same Boecillo Technological Park address (13 Louis Proust Street) as BDi. Offers strain development, process development, and GMP manufacturing services for biologics — making it the closest direct competitor for both clients and talent.
• Biovian: Finland-based microbial CDMO providing GMP manufacturing of biologics, cell and gene therapies, and ATMPs from microbial and mammalian hosts. Comparable in scale and service breadth to BDi, with similar microbial CDMO positioning.

Broad incumbents

• Aenova: German-headquartered full-service CDMO offering development, manufacturing, and packaging across solid dosage, sterile liquids, and biologics. Competes with BDi in fermentation-related services but with a much broader pharma manufacturing portfolio.
• Recipharm: Swedish CDMO with broad contract manufacturing capabilities across biologics, sterile fill-finish, and oral solids. Competes for outsourced pharmaceutical manufacturing budgets and overlaps with BDi in biologic process development and manufacturing.
• Lonza: Global Swiss CDMO leader in microbial and mammalian biologics manufacturing. Sets the benchmark for scale, regulatory track record, and cGMP capacity — competes with BDi for outsourced fermentation and biopharma projects, particularly at the commercial scale-up stage.
• Catalent (Novo Holdings): Global CDMO with extensive biologics, oral, and inhalation capabilities. Recently acquired by Novo Holdings. Provides the full development-to-commercialization pathway that BDi's mid-scale platform must compete against for upstream biotech outsourcing decisions.
• AGC Biologics: Global CDMO focused on mammalian and microbial biologics, cell and gene therapies, and messenger RNA. Competes with BDi in microbial CDMO services with substantially larger multi-site capacity and established large-pharma relationships.
• Novonesis (formerly Chr. Hansen): Global bioscience company with deep capabilities in microbial fermentation, enzymes, probiotics, and cultures for food, health, and agriculture. Overlaps with BDi's nutraceuticals and probiotics fermentation services at a vastly larger scale.
• Lallemand: Canadian-headquartered global manufacturer of yeast, bacteria, and fermentation-based products for baking, food, beverage, and health/nutrition markets. Overlaps directly with BDi's probiotic, enzyme, and microbial CDMO services.

Regional players

• PharmaMar: Spanish biopharmaceutical company developing marine-derived oncology therapeutics. While primarily a product company rather than a CDMO, it is a comparable Spanish-headquartered biotech of similar size and signals the broader Spanish biotech ecosystem in which BDi operates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/bdibiotech
• LinkedInlinkedin.com/company/bdi-biotech

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BDi Biotechnology Group